TABLE 4.
Endpoints | Number of Studies |
---|---|
Prevention of complications of cirrhosis | |
SBP | 4 |
CHE | 3 |
Decompensated cirrhosis | 2 |
HE in patients with transjugular intrahepatic portosystemic shunts | 2 |
ACLF* | 1 |
Variceal bleeding | 1 |
Renal failure | 1 |
Persistent HE | 1 |
Other | |
Portal pressure | 2 |
Systemic inflammation | 1 |
B‐cell dysregulation | 1 |
Portal vein thrombosis | 1 |
Quality of life | 1 |
Associated with simvastatin.